Fosun Pharma subsidiary signs potential $1.9bn Pfizer licence deal

YP05002, developed by Yao Pharma, is in Phase 1 clinical development in Australia and can potentially help with metabolic diseases; Yao Pharma will receive an upfront payment of $150m for a worldwide licence.

Andrew Tjaardstra

December 11, 2025

Chongqing Yao Pharmaceutical Company (Yao Pharma) and Shanghai Fosun Pharmaceutical Industrial Development Company, both subsidiaries of Fosun Pharma, have entered into an exclusive collaboration and licence agreement with US pharmaceutical giant Pfizer, according to a December announcement.

Sign In to Your Account To Access Exclusive FinanceAsia Content!

Please sign in to your subscription to unlock full access to our premium FA resources.

Free Registration & 7-Day Trial
Register now to enjoy a 7-day free trial - no registration fees required. Click the link to get started.

Note: This free trial is a one-time offer.

Questions?
If you have any enquiries or would like a quote for a team or company licence, please contact us at [email protected]. Our subscription team will be happy to assist you.